Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tamoxifen citrate
Drug ID BADD_D02112
Description Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole].[A1026] Tamoxifen was granted FDA approval on 30 December 1977.[L7799]
Indications and Usage Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.[L7802]
Marketing Status approved
ATC Code L02BA01
DrugBank ID DB00675
KEGG ID D00966
MeSH ID D013629
PubChem ID 2733525
TTD Drug ID D07KSG
NDC Product Code 65319-1151; 51407-440; 51862-642; 0378-0274; 17337-0035; 46014-1015; 46014-1190; 49452-7571; 51927-5076; 63275-9865; 59651-299; 70518-2721; 70771-1185; 46014-1200; 51862-682; 70771-1184; 51552-0838; 51862-643; 51407-439; 68382-826; 36974-0048; 0378-0144; 51927-2976; 63187-976; 0591-2472; 17337-0034; 50090-0485; 59651-300; 68382-827; 46014-1180; 63739-143; 68071-5254; 0591-2473; 65319-1051
UNII 7FRV7310N6
Synonyms Tamoxifen | ICI-47699 | ICI 47699 | ICI47699 | Nolvadex | Novaldex | Tamoxifen Citrate | Citrate, Tamoxifen | Tomaxithen | Zitazonium | ICI-46474 | ICI 46474 | ICI46474 | ICI-46,474 | ICI 46,474 | ICI46,474 | Soltamox
Chemical Information
Molecular Formula C32H37NO8
CAS Registry Number 54965-24-1
SMILES CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O) O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pancreatitis07.18.01.001--
Pancytopenia01.03.03.003--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Paralysis17.01.04.004--Not Available
Peliosis hepatis09.01.07.010--Not Available
Pelvic pain07.01.06.012; 21.10.01.001; 20.02.03.007--
Pemphigoid23.03.01.004; 10.04.02.002--Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Phlebitis superficial24.12.03.005--Not Available
Platelet count decreased13.01.04.001--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Porphyria non-acute23.03.01.012; 14.14.01.004; 03.08.01.004; 09.01.10.003--Not Available
Priapism24.04.12.007; 21.03.01.005--Not Available
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Rash23.03.13.001--Not Available
Retinal disorder06.08.03.005--Not Available
Sarcoma16.33.01.002; 15.09.03.002--Not Available
Sarcoma uterus21.07.02.005; 16.33.01.001--Not Available
Sensory loss17.02.07.007--Not Available
Sepsis11.01.11.003--
Sinusitis11.01.13.005; 22.07.03.007--
Skin exfoliation23.03.07.003--Not Available
Spinal fracture15.08.05.001; 12.04.04.002--
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Swelling08.01.03.015--Not Available
Tenderness08.01.08.005--Not Available
Thirst08.01.09.021; 14.03.02.007--Not Available
Throat irritation22.12.03.029; 07.05.05.037--Not Available
Thrombocytopenia01.08.01.002--Not Available
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages